Athersys (NASDAQ:ATHX) Coverage Initiated at StockNews.com

StockNews.com assumed coverage on shares of Athersys (NASDAQ:ATHXFree Report) in a report published on Thursday. The firm issued a hold rating on the biopharmaceutical company’s stock.

Athersys Stock Down 33.5 %

Shares of ATHX opened at $0.01 on Thursday. The firm has a market capitalization of $833,206.50, a price-to-earnings ratio of -0.01 and a beta of -0.90. Athersys has a 52-week low of $0.01 and a 52-week high of $1.99.

About Athersys

(Get Free Report)

Athersys, Inc, a biotechnology company, focuses on the research and development activities in the field of regenerative medicine. Its clinical development programs are focused on treating neurological conditions, cardiovascular diseases, inflammatory and immune disorders, and pulmonary and other conditions.

Read More

Receive News & Ratings for Athersys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Athersys and related companies with MarketBeat.com's FREE daily email newsletter.